Verastem appoints new COO with extensive biotech experience
NEEDHAM, MA - Verastem, Inc. (NASDAQ:VSTM), a $247.5 million market cap biopharmaceutical company focused on developing and ...
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital
Verastem, Inc. (NASDAQ: VSTM) recently disclosed in an 8-K filing with the Securities and Exchange Commission that on January 13, 2025, the company entered into a Note Purchase Agreement with RGCM SA ...